TFAP2E-DKK4 and chemoresistance in colorectal cancer
To the Editor: Ebert et al. (Jan. 5 issue)1 report that hypermethylation of the gene encoding transcription factor AP-2 epsilon (TFAP2E) reduces its expression and is associated with chemoresistance in patients with colorectal cancer and in colorectal-cancer cell lines in vitro. The test has dramati...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) Editorial |
| Sprache: | Englisch |
| Veröffentlicht: |
March 8, 2012
|
| In: |
The New England journal of medicine
Year: 2012, Jahrgang: 366, Heft: 10, Pages: 966-966 |
| ISSN: | 1533-4406 |
| DOI: | 10.1056/NEJMc1201170 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1056/NEJMc1201170
|
| Verfasserangaben: | Matthias P.A. Ebert, M.D., Marc Tänzer, M.A. |
| Zusammenfassung: | To the Editor: Ebert et al. (Jan. 5 issue)1 report that hypermethylation of the gene encoding transcription factor AP-2 epsilon (TFAP2E) reduces its expression and is associated with chemoresistance in patients with colorectal cancer and in colorectal-cancer cell lines in vitro. The test has dramatic clinical value: the response rate increased from less than 15% among hypomethylated tumors to more than 80% among hypermethylated tumors. Methylation of this gene had a huge biologic and clinical effect. However, we have several questions. First, the methylation status differs between primary tumors and metastases in approximately 30% of tumors: were these tumors considered . . . |
|---|---|
| Beschreibung: | Gesehen am 16.04.2019 |
| Beschreibung: | Online Resource |
| ISSN: | 1533-4406 |
| DOI: | 10.1056/NEJMc1201170 |